C4 Therapeutics, Inc. CCCC
Set alert
3.21 USD -0.16 -4.75%
At close
3.18 -0.03 -0.93%
Pre-market · Nov 3, 5:29 AM ET
3.16 Day range 3.41
1.69 52-week range 5.17
- YTD
- +68.06%
- 1 year
- +29.44%
- Open
- 3.36
- Prev close
- 3.37
- Mkt cap
- 394.91M
- Vol
- 2.86M
- Avg vol
- 2.43M
- EPS
- -0.91
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.16
- High
- 3.41
- Forward P/E
- -2.37
- Beta
- 3.06
- Short ratio
- 7.10
- Inst. own
- 91.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 1, 2024
- 50-d avg
- 5.06
- 200-d avg
- 5.96
- 1y target
- 15.00
Analyst view
Consensus: buy
Buy
Price target (mean) 15.00 +367.3% upside
Now 3.21
- Target (low)
- 4.00
- Target (mean)
- 15.00
- Target (high)
- 39.00
Ratings (0m) 9 6 buy · 3 hold · 0 sell
- Strong buy1
- Buy5
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 9
- 1 month ago 9
- 2 months ago 8
- 3 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.44 | -0.59 – -0.26 | -0.68 | +35.3% | 4.33M | +32.9% | 3 |
| Next quarter | 0.605 | -0.31 – 1.52 | -0.37883 | +259.7% | 2.50M | -17.7% | 2 |
| Current year | -1.36 | -1.61 – -0.97 | -2.66 | +48.8% | 35.82M | +72.6% | 3 |
| Next year | -1.12 | -1.80 – 0.36 | -1.36 | +17.6% | 38.91M | +8.6% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | Wells Fargo | Upgrade | Equal-Weight | Overweight |
| Nov 18, 2024 | Stephens & Co. | Initiated | — | Equal-Weight |
| Aug 6, 2024 | BMO Capital | Reiterated | Outperform | Outperform |
| May 9, 2024 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| May 9, 2024 | Stifel | Maintained | Buy | Buy |
| Feb 26, 2024 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Feb 23, 2024 | Stifel | Reiterated | Buy | Buy |
| Jan 29, 2024 | JP Morgan | Upgrade | Underweight | Neutral |
| Dec 13, 2023 | Stifel | Upgrade | Hold | Buy |
| Nov 6, 2023 | Morgan Stanley | Upgrade | Underweight | Equal-Weight |
| Nov 3, 2023 | BMO Capital | Maintained | Outperform | Outperform |
| Nov 2, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 9, 2023 | B of A Securities | Maintained | Neutral | Neutral |
| Aug 9, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 30, 2023 | Evercore ISI Group | Maintained | — | Outperform |
| May 12, 2023 | Morgan Stanley | Maintained | Underweight | Underweight |
| May 8, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Mar 28, 2023 | B of A Securities | Maintained | — | Neutral |
| Feb 27, 2023 | Morgan Stanley | Maintained | — | Underweight |
| Feb 24, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Feb 24, 2023 | JP Morgan | Downgrade | Neutral | Underweight |
| Jan 3, 2023 | Wells Fargo | Maintained | — | Equal-Weight |
| Nov 8, 2022 | Wells Fargo | Maintained | — | Equal-Weight |
| Nov 4, 2022 | JP Morgan | Downgrade | Overweight | Neutral |
| Oct 11, 2022 | Morgan Stanley | Initiated | — | Underweight |
| May 9, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Apr 28, 2022 | Credit Suisse | Initiated | — | Underperform |
| Apr 18, 2022 | UBS | Maintained | — | Buy |
| Apr 11, 2022 | BMO Capital | Maintained | — | Outperform |
| Mar 10, 2022 | JP Morgan | Initiated | — | Overweight |